Wegovy Tablets Vs Injections

If you have been researching weight loss medication, you have almost certainly come across the name Wegovy. It has dominated headlines, sparked conversations in GP surgeries, and become one of the most talked-about treatments for obesity in the UK. But one question keeps coming up time and again: do Wegovy tablets actually exist, and if not, what are your real options for effective, medically approved weight loss treatment?

Quick Summary

Wegovy is a semaglutide-based weight loss treatment currently available only as a subcutaneous injection in the UK. There are no approved Wegovy tablets on the market at this time, though oral semaglutide research is advancing rapidly heading into 2026.

• Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces appetite and promotes weight loss
• It is currently only available as a pre-filled injection pen, not as a tablet
• Clinical trials show users can lose up to 15% of their body weight over 68 weeks
• Alternative weight loss options including Mounjaro weight loss injections (tirzepatide) and Orlos (Orlistat) 60mg weight loss capsules are available in the UK
• Always consult a qualified UK prescriber before starting any weight loss medication

Table of Contents

1. What Is Wegovy and How Does It Work?
2. Do Wegovy Tablets Actually Exist in the UK?
3. How to Use Wegovy: Dosing, Injection Sites, and Schedule
4. Common Side Effects and How to Manage Them
5. Wegovy Alternatives Available in the UK Right Now
6. Who Qualifies for Wegovy and Weight Loss Medication in the UK?
7. Key Takeaways
8. When to Seek Professional Advice
9. Frequently Asked Questions

What Is Wegovy and How Does It Work?

Wegovy is the brand name for semaglutide 2.4mg, a medication developed by Novo Nordisk and licensed in the UK specifically for chronic weight management. It belongs to a class of drugs known as GLP-1 receptor agonists, which mimic the action of a naturally occurring gut hormone called glucagon-like peptide-1. This hormone plays a central role in appetite regulation, gastric emptying, and blood sugar control. When semaglutide activates GLP-1 receptors in the brain, it signals feelings of fullness and reduces the urge to eat, making it far easier to maintain a calorie deficit without the constant hunger that derails so many weight loss attempts.

Understanding the biology behind Wegovy tablets helps explain why this treatment has been such a game-changer for people living with obesity. Unlike older diet pills that worked through stimulant-like mechanisms or simply blocking fat absorption, semaglutide targets the root cause of overeating at a hormonal level. People who use it often describe a noticeable quietening of food noise — that persistent mental preoccupation with eating that makes traditional dieting so psychologically exhausting.

The STEP clinical trial programme, which involved over 4,500 participants across multiple countries, demonstrated that semaglutide 2.4mg produced average weight reductions of around 14.9% of body weight over 68 weeks when combined with diet and exercise. For many participants, this represented a life-changing improvement in metabolic health markers including blood pressure, cholesterol, and blood glucose levels. These results were significant enough to prompt NICE to issue guidance supporting the use of semaglutide within NHS specialist weight management services.

• Mimics the GLP-1 gut hormone to reduce hunger signals in the brain
• Slows gastric emptying, helping you feel fuller for longer after meals
• Reduces food preoccupation, often described as silencing food noise
• Improves insulin sensitivity and supports better blood sugar control
• Clinical evidence supports average weight loss of nearly 15% over 68 weeks

Do Wegovy Tablets Actually Exist in the UK?

This is the question that brings many people to this page, and it deserves a clear, honest answer. As of 2026, there are no approved Wegovy tablets available in the UK or anywhere else in the world. Wegovy is exclusively formulated as a subcutaneous injection, delivered via a pre-filled pen device once per week. The semaglutide molecule, in its current form, is a peptide — a type of protein — that is broken down by the digestive system before it can be absorbed into the bloodstream when taken by mouth. This is precisely why injection remains the only clinically validated delivery method for Wegovy at its therapeutic dose.

However, there is genuine scientific progress happening in this space. Oral semaglutide does exist in a lower-dose tablet form under the brand name Rybelsus, but this product is licensed only for type 2 diabetes management, not weight loss, and at doses far lower than those used in Wegovy. Research into higher-dose oral semaglutide formulations for obesity is ongoing, with several promising Phase 3 trials reporting encouraging results. The pharmaceutical landscape may look quite different in the coming years, but right now, if you see anyone claiming to sell Wegovy in tablet form, this should be treated as a significant red flag regarding product legitimacy and safety.

The confusion around Wegovy tablets is completely understandable. Tablets are familiar, non-invasive, and carry none of the psychological barrier that injections can pose for some people. Many individuals are genuinely needle-averse, and the idea of a weekly injection can feel like a dealbreaker. If that resonates with you, it is worth speaking to a prescriber about the full range of options available, including non-injectable weight loss aids such as XLS Medical Weight Loss Plus tablets, which work through a different mechanism and are available without a prescription.

• No approved Wegovy tablet product exists in the UK as of 2026
• Oral semaglutide (Rybelsus) exists but is licensed only for type 2 diabetes
• Semaglutide peptide structure means it is degraded in the stomach at high doses
• Any product claiming to be Wegovy tablets should be treated with extreme caution
• Ongoing clinical research may deliver oral options in future years

How to Use Wegovy: Dosing, Injection Sites, and Schedule

One of the most common concerns people have about starting any injection-based treatment is the practical reality of self-administering it at home. The good news is that Wegovy has been designed to be as straightforward and discreet as possible. The pre-filled pen device contains a very fine, short needle, and the injection is given subcutaneously — meaning just beneath the skin — rather than into a muscle. Most people find that after the first few uses, the process becomes quick and almost entirely painless. Many describe it as far less intimidating than they initially feared.

Wegovy follows a gradual dose escalation protocol specifically designed to give your body time to adjust and to minimise gastrointestinal side effects. You begin on a very low dose and increase every four weeks until you reach the full therapeutic dose. This step-up approach is one of the key reasons that Wegovy tends to be better tolerated than older weight loss medications, and it is an important part of what makes it clinically effective over the long term.

Week	Dose	Purpose	Expected Tolerability
Weeks 1–4	0.25mg once weekly	Introduction and adjustment	Generally well tolerated; mild nausea possible
Weeks 5–8	0.5mg once weekly	Gradual dose escalation	Appetite reduction begins; some GI symptoms
Weeks 9–12	1mg once weekly	Continued escalation	Noticeable weight loss; nausea often reduces
Weeks 13–16	1.7mg once weekly	Pre-maintenance escalation	Stronger appetite suppression
Week 17 onwards	2.4mg once weekly	Full therapeutic maintenance dose	Maximum efficacy; side effects typically stabilised

The injection can be given in the abdomen, upper arm, or thigh. Rotating the injection site is recommended to prevent localised skin reactions. Wegovy should always be stored in the fridge between 2°C and 8°C, though it can be kept at room temperature (below 30°C) for up to 28 days once out of the fridge. Always check the pen for any visible particles or discolouration before use, and never share your pen with another person.

• Inject once weekly on the same day each week for best results
• Suitable injection sites include the abdomen, upper arm, and thigh
• Rotate sites each week to avoid skin irritation
• Store in the fridge; can be out of the fridge for up to 28 days
• Follow the dose escalation schedule strictly as advised by your prescriber

Common Side Effects and How to Manage Them

Like any prescription medication, Wegovy can cause side effects, particularly in the early weeks of treatment when your body is adjusting to the new hormone stimulus. The most frequently reported side effects are gastrointestinal in nature, and this is directly linked to the way semaglutide slows gastric emptying. For most people, these effects are temporary, manageable, and significantly improve after the first few weeks on each new dose level. Understanding what to expect can help you push through that initial adjustment period and reach the point where the benefits far outweigh the discomfort.

Nausea is by far the most commonly reported side effect, affecting a significant proportion of users during dose escalation. It is usually mild to moderate and tends to be worst in the hours immediately after injection. Eating smaller meals, avoiding rich or fatty foods, and staying well hydrated can all make a meaningful difference. Vomiting, diarrhoea, and constipation are also possible but typically resolve over time. More serious side effects, though rare, include pancreatitis, gallbladder problems, and an increased resting heart rate. These should be discussed thoroughly with your prescriber before starting treatment.

It is also worth knowing that certain people should not use Wegovy. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pregnant or breastfeeding women should not use this medication. People with a history of serious hypersensitivity reactions to semaglutide should also avoid it. Your prescriber will conduct a full medical assessment to ensure Wegovy is appropriate for you before issuing a prescription. If you are exploring over-the-counter support in the meantime, XLS Medical Direct Fat Binder sachets may provide a gentler starting point for some individuals.

• Nausea is the most common side effect, typically worse during dose escalation
• Eat smaller portions and avoid greasy foods to reduce nausea
• Diarrhoea and constipation may occur but usually improve within weeks
• Rare but serious risks include pancreatitis and gallbladder disease
• Report any severe abdominal pain, vision changes, or allergic reactions immediately

Wegovy Alternatives Available in the UK Right Now

Even though there is no tablet version of Wegovy, there are several effective weight loss treatments available in the UK that cater to different preferences, medical histories, and eligibility criteria. If needle aversion is the primary concern, it is worth knowing that many people adapt to self-injection very quickly, especially with the support of a knowledgeable prescriber or pharmacist. That said, legitimate alternatives exist and may be equally appropriate depending on your individual circumstances.

Tirzepatide, marketed as Mounjaro, is a dual GIP and GLP-1 receptor agonist that has shown even greater weight loss potential than semaglutide in head-to-head clinical data. In the SURMOUNT trials, participants lost an average of over 20% of their body weight, making it one of the most powerful weight loss medicines currently licensed in the UK. Like Wegovy, it is administered as a once-weekly subcutaneous injection. Orlistat, available as Orlos Orlistat 60mg capsules, works by blocking approximately 30% of dietary fat absorption in the gut and is available without a prescription, making it the most accessible pharmaceutical weight loss option in the UK.

For those seeking a more holistic approach, lifestyle-focused supplements and diet products can complement any weight management programme. Products like Formoline L112 tablets bind dietary fat in the gut and may support a reduced-calorie diet. These are not substitutes for prescription treatment in people with clinical obesity, but they can play a useful supporting role for those with a lower BMI who do not meet eligibility criteria for prescription GLP-1 therapy.

• Mounjaro (tirzepatide) offers superior weight loss results to semaglutide in trials
• Orlistat is the only prescription-strength oral weight loss medicine approved in the UK
• OTC options like Formoline L112 suit those who do not qualify for prescription treatment
• Lifestyle changes including dietary adjustments and regular exercise remain fundamental
• Speak to a prescriber to identify the most clinically appropriate option for you

Who Qualifies for Wegovy and Weight Loss Medication in the UK?

Access to prescription weight loss medication in the UK is determined by specific clinical criteria designed to ensure treatment reaches those who will benefit most. For NHS access to semaglutide-based treatment, NICE guidance recommends it for adults with a BMI of at least 35 kg/m² alongside at least one weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnoea. It may also be considered at a BMI of 30 kg/m² or above in certain high-risk groups. In 2026, NHS specialist services continue to operate waiting lists, meaning many eligible patients are turning to private prescription services to access treatment more quickly.

Through regulated online pharmacy services such as Cured Pharmacy, a qualified UK prescriber will carry out a thorough online medical consultation to assess your suitability. This typically includes questions about your BMI, medical history, current medications, and weight loss goals. If the prescriber determines that Wegovy or an alternative medication is appropriate, a prescription can be issued and the treatment dispatched discreetly to your home. This route provides a safe, regulated alternative for those who cannot access NHS treatment promptly, and all prescriptions are issued in line with MHRA and GPhC standards.

It is important to understand that weight loss medication is not a magic solution in isolation. The clinical evidence is clear that the best outcomes come from combining medication with sustainable dietary changes, increased physical activity, and psychological support where needed. Your prescriber should discuss this holistic approach with you at the outset. Monitoring your thyroid health can also be relevant during obesity treatment, and some patients benefit from a thyroid test to rule out underlying thyroid conditions that can affect weight.

• NHS criteria require a BMI of 35 kg/m² or above plus a weight-related condition
• Private prescriptions are available via regulated UK online pharmacies
• A thorough online medical consultation is required before any prescription is issued
• Medication must be combined with diet, exercise, and behavioural support for best results
• Thyroid function testing can be useful to rule out underlying metabolic conditions

Key Takeaways

• Wegovy is a semaglutide injection, not a tablet — no oral form is currently approved for weight loss in the UK
• It works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and promote sustained weight loss
• Clinical trials demonstrate average weight loss of up to 15% of body weight over 68 weeks
• Effective alternatives include Mounjaro (tirzepatide), Orlistat, and OTC fat binders for those who do not qualify for GLP-1 therapy
• Always obtain weight loss medication through a regulated UK prescriber to ensure your safety and treatment efficacy

When to Seek Professional Advice

Weight loss medication is not suitable for everyone, and there are certain situations where you should seek medical advice promptly rather than proceeding with self-treatment. If you experience severe abdominal pain that radiates to your back, persistent vomiting, yellowing of the skin or eyes, or any signs of an allergic reaction such as swelling of the face or throat, stop taking your medication and seek urgent medical attention. These symptoms may indicate rare but serious complications including pancreatitis or gallbladder disease.

You should also consult a healthcare professional if you notice a rapid or irregular heartbeat, worsening kidney function, or unexplained changes in vision, as these may require a review of your treatment. If your weight loss has plateaued despite adherence to your treatment plan, a clinical review is warranted to assess whether your dose should be adjusted or an alternative considered. Anyone with a personal or family history of thyroid cancer, or who is planning a pregnancy, should discuss this with their prescriber before starting or continuing semaglutide treatment.

Frequently Asked Questions

How long does it take for Wegovy to start working?

Wegovy typically starts working within the first few weeks, with most people noticing reduced appetite and early weight loss within four to eight weeks of starting treatment. Significant results, usually five percent or more of body weight, are generally seen by week twelve, with the greatest benefits achieved after 68 weeks of consistent use.

Is Wegovy safe to use long term?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. Clinical trials lasting up to 68 weeks demonstrated a strong safety profile. Ongoing monitoring of heart rate, blood pressure, and any gastrointestinal symptoms is recommended, and your prescriber will review your treatment regularly.

Can you take Wegovy with other weight loss supplements?

Taking Wegovy alongside other weight loss supplements is not generally recommended without medical guidance. Combining treatments can increase the risk of side effects such as nausea, dizziness, or altered blood sugar levels. Always inform your prescriber or pharmacist about any other supplements or medications you are taking before starting Wegovy.

What is the starting dose of Wegovy?

The starting dose of Wegovy is 0.25mg once weekly, injected subcutaneously. This low introductory dose helps your body adjust gradually and minimise gastrointestinal side effects. The dose is then escalated every four weeks, progressing through 0.5mg, 1mg, and 1.7mg, until reaching the maintenance dose of 2.4mg weekly.

Scientific References

1. NICE Technology Appraisal TA875: Semaglutide for managing overweight and obesity — National Institute for Health and Care Excellence (2023)
2. Wegovy 2.4mg Solution for Injection Summary of Product Characteristics — Electronic Medicines Compendium (eMC), Novo Nordisk
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine (2021)